QURE insider trading
NasdaqGS HealthcareuniQure N.V. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Company website: www.uniqure.com
QURE insider activity at a glance
FilingIQ has scored 601 insider transactions for QURE since Jan 27, 2017. The most recent filing in our index is dated May 8, 2026.
Across the full history, 0 open-market purchases
and 340 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on QURE insider trades is 60.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest QURE Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading QURE
Frequently asked
- How many insider trades does FilingIQ track for QURE?
- FilingIQ tracks 601 Form 4 insider transactions for QURE (uniQure N.V.), covering filings from Jan 27, 2017 onwards. 24 of those were filed in the last 90 days.
- Are QURE insiders net buyers or net sellers?
- Across the full Form 4 history for QURE, 0 transactions (0%) were open-market purchases and 340 (57%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does QURE insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is QURE in?
- uniQure N.V. (QURE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.52B.
Methodology & sources
Every QURE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.